A Phase 1 Study To Evaluate The Pharmacokinetics Of Ag-013736 In Subjects With Impaired Hepatic Function.

Trial Profile

A Phase 1 Study To Evaluate The Pharmacokinetics Of Ag-013736 In Subjects With Impaired Hepatic Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs Axitinib (Primary)
  • Indications Colorectal cancer; Liver cancer; Renal cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Mar 2016 Results assessing pharmacokinetics from this other trial presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 21 Nov 2008 Actual start date changed from June 2008 to May 2008, actual end date reported as October 2008 by ClinicalTrials.gov.
    • 21 Nov 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top